Literature DB >> 24484247

Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors.

Pramod V Butte1, Adam Mamelak, Julia Parrish-Novak, Doniel Drazin, Faris Shweikeh, Pallavi R Gangalum, Alexandra Chesnokova, Julia Y Ljubimova, Keith Black.   

Abstract

OBJECT: The intraoperative clear delineation between brain tumor and normal tissue in real time is required to ensure near-complete resection without damaging the nearby eloquent brain. Tumor Paint BLZ-100, a tumor ligand chlorotoxin (CTX) conjugated to indocyanine green (ICG), has shown potential to be a targeted contrast agent. There are many infrared imaging systems in use, but they are not optimized to the low concentration and amount of ICG. The authors present a novel proof-of-concept near-infrared (NIR) imaging system using a standard charge-coupled device (CCD) camera for visualizing low levels of ICG attached to the tumors. This system is small, inexpensive, and sensitive. The imaging system uses a narrow-band laser at 785 nm and a notch filter in front of the sensor at the band. The camera is a 2-CCD camera, which uses identical CCDs for both visible and NIR light.
METHODS: The NIR system is tested with serial dilution of BLZ-100 from 1 μM to 50 pM in 5% Intralipid solution while the excitation energy is varied from 5 to 40 mW/cm(2). The analog gain of the CCD was changed from 0, 6, and 12 dB to determine the signal-to-noise ratio. In addition to the Intralipid solution, BLZ-100 was injected 48 hours before euthanizing the mice that were implanted with the human glioma cell line. The brain was removed and imaged using the NIR imaging system.
RESULTS: The authors' results show that the NIR imaging system using a standard CCD is able to visualize the ICG down to 50 nM of concentration with a high signal-to-noise ratio. The preliminary experiment on human glioma implanted in mouse brains demonstrated that BLZ-100 has a high affinity for glioma compared with normal brain tissue. Additionally, the results show that NIR excitation is able to penetrate deeply and has a potential to visualize metastatic lesions that are separate from the main tumor.
CONCLUSIONS: The authors have seen that BLZ-100 has a very high affinity toward human gliomas. They also describe a small, cost-effective, and sensitive NIR system for visualizing brain tumors tagged using BLZ-100. The authors hope that the use of BLZ-100 along with NIR imaging will be useful to delineate the brain tumors in real time and assist surgeons in near-complete tumor removal to increase survival and reduce neurological deficits.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24484247     DOI: 10.3171/2013.11.FOCUS13497

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  42 in total

1.  Augmented microscopy: real-time overlay of bright-field and near-infrared fluorescence images.

Authors:  Jeffrey R Watson; Christian F Gainer; Nikolay Martirosyan; Jesse Skoch; G Michael Lemole; Rein Anton; Marek Romanowski
Journal:  J Biomed Opt       Date:  2015-10       Impact factor: 3.170

2.  Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.

Authors:  Derek Reichel; Bien Sagong; James Teh; Yi Zhang; Shawn Wagner; Hongqiang Wang; Leland W K Chung; Pramod Butte; Keith L Black; John S Yu; J Manuel Perez
Journal:  ACS Nano       Date:  2020-06-23       Impact factor: 15.881

3.  Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent.

Authors:  Julia Parrish-Novak; Kelly Byrnes-Blake; Narine Lalayeva; Stefanie Burleson; Janean Fidel; Rhonda Gilmore; Pamela Gayheart-Walsten; Gregory A Bricker; William J Crumb; K S Tarlo; Stacey Hansen; Valorie Wiss; Errol Malta; William S Dernell; James M Olson; Dennis M Miller
Journal:  Int J Toxicol       Date:  2017-03-17       Impact factor: 2.032

4.  Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme.

Authors:  Rameshwar Patil; Anna Galstyan; Tao Sun; Ekaterina S Shatalova; Pramod Butte; Adam N Mamelak; Christine Carico; David S Kittle; Zachary B Grodzinski; Antonella Chiechi; Hui Ding; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Biomaterials       Date:  2019-03-23       Impact factor: 12.479

Review 5.  Fluorescent-Guided Surgical Resection of Glioma with Targeted Molecular Imaging Agents: A Literature Review.

Authors:  Sonya E L Craig; James Wright; Andrew E Sloan; Susann M Brady-Kalnay
Journal:  World Neurosurg       Date:  2016-02-23       Impact factor: 2.104

Review 6.  Oncologic Procedures Amenable to Fluorescence-guided Surgery.

Authors:  Kiranya E Tipirneni; Jason M Warram; Lindsay S Moore; Andrew C Prince; Esther de Boer; Aditi H Jani; Irene L Wapnir; Joseph C Liao; Michael Bouvet; Nicole K Behnke; Mary T Hawn; George A Poultsides; Alexander L Vahrmeijer; William R Carroll; Kurt R Zinn; Eben Rosenthal
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

Review 7.  Image-Guided Tumor Resection.

Authors:  Julia Parrish-Novak; Eric C Holland; James M Olson
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

8.  Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors.

Authors:  Janean Fidel; Katie C Kennedy; William S Dernell; Stacey Hansen; Valorie Wiss; Mark R Stroud; Joshua I Molho; Sue E Knoblaugh; Jeffrey Meganck; James M Olson; Brad Rice; Julia Parrish-Novak
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

Review 9.  Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates.

Authors:  Yongjun Cheng; Jinhua Zhao; Wenli Qiao; Kai Chen
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

10.  Development and evaluation of a connective tissue phantom model for subsurface visualization of cancers requiring wide local excision.

Authors:  Kimberley S Samkoe; Brent D Bates; Niki N Tselepidakis; Alisha V DSouza; Jason R Gunn; Dipak B Ramkumar; Keith D Paulsen; Brian W Pogue; Eric R Henderson
Journal:  J Biomed Opt       Date:  2017-12       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.